Tevogen Bio (TVGN) said Monday it expects revenue of nearly $1 billion for its specialty care pipeline in the launch year.
The company estimates its cumulative specialty care revenue over five years to range between $18 billion and $22 billion.
Price: 1.7500, Change: -0.05, Percent Change: -2.78